Page 69 - Helicobacter pylori and Gastric Cancer: From Tumor microenvironment to Immunotherapy

Immunotherapy Checkpoint Inhibition
Immuno checkpoint inhibition
63
67
3
Table 2. Characteristic of ongoing immune checkpoint clinical trials in gastric cancer.
Study/ Clinical trial identification/Refe Clinical trial Phase
Strategy
Status
Indication
Roy S et al., 2016/published/(69) 1
Pembrolizumab in combination with ramucirumab Pembrolizumab in combination with PEGPH20
Recruiting
Defined group, second or third line regimen
Defined group, at least second line
Philip et al., 2016/published/(70) NCT02563548 1
Recruiting Active, not recruiting Recruiting Recruiting Recruiting
Muro et al., 2016/published/ NCT01848834 1 (KEYNOTE 012)(71)
Pembrolizumab
Defined group ,non- relapsed setting
Defined group , non- relapsed setting
Zev et al., 2016/published/ NCT02452424(72) 1
Pembrolizumab in combination with PLX3397
Karen et al., 2016/published/
NCT01772004/(73)
Yasuhide et al., 2016/published/ 1 NCT01943461/(74)
Defined group, third line
Howard et al., 2017/published/ NCT01633970/(75)
MPDL3280A with bevacizumab
1 administered as monotherapy or
Recruiting
Basket trial
David et al., 2016/published/
NCT01375842/(76)
Jessica et al., 2016/published/ 1 NCT02471846/(77)
Recruiting Recruiting
Basket trial
2016/published/ NCT02318901 1/2 2016/published/ NCT02268825 01/2
Pembrolizumab with trastuzumab as combination
Recruiting
Ronan et al., 2016/published/
1b/2 Tremelimumab MEDI4736 Ipilimumab versus. FU/BSC Nivolumab +/- ipilimumab
Recruiting Recruiting Completed
non- relapsed setting
NCT02340975(78)
Jedd et al., 2016/published/ NCT01585987(79) 2
Maintenance after 1st line
Antonia et al., 2016/published/ 1/2
Defined group , non- relapsed setting
NCT01928394(80)
Jeed et al., 2016/published/ NCT02488759(81) 1/2
Nivolumab Recruiting
Epstein–Barr virus -positive 1st Line, HER2-negative, PDL1- positive
Josep et al., 2016/published/ NCT02494583 3 (KEYNOTE 062)(82)
Pembrolizumab monotherapy or combination with CT
Recruiting Second line
Atsushi et al., 2016/published/ NCT02370498 (KEYNOTE 061)(83)
3 Pembrolizumab verse. paclitaxel
Enrolling
1 Avelumab
Avelumab
second and third line, Asian and Japanese
as combined therapy 1 MPDL3280A
MPDL3280A and GDC-0919
Defined group , non- relapsed setting
Defined group, human epidermal growth factor receptor 2) - positive
Pembrolizumab in combination with FOLFOX
Recruiting
Defined group